Fluoroquinolone antimicrobial drugs - PubMed (original) (raw)

Fluoroquinolone antimicrobial drugs

Tiffany Chan et al. CMAJ. 2017.

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Similar articles

• The newer fluoroquinolones.
  Bolon MK. Bolon MK. Infect Dis Clin North Am. 2009 Dec;23(4):1027-51, x. doi: 10.1016/j.idc.2009.06.003. Infect Dis Clin North Am. 2009. PMID: 19909896 Review.
• Antimicrobial activity of DW-224a, a new fluoroquinolone, against Streptococcus pneumoniae.
  Kim HJ, Seol MJ, Park HS, Choi DR, Seong SK, Shin HK, Kwak JH. Kim HJ, et al. J Antimicrob Chemother. 2006 Jun;57(6):1256-8. doi: 10.1093/jac/dkl144. Epub 2006 Apr 7. J Antimicrob Chemother. 2006. PMID: 16603643 No abstract available.
• Fluoroquinolone-Resistant Mycoplasma genitalium, Southwestern France.
  Le Roy C, Hénin N, Pereyre S, Bébéar C. Le Roy C, et al. Emerg Infect Dis. 2016 Sep;22(9):1677-9. doi: 10.3201/eid2209.160446. Emerg Infect Dis. 2016. PMID: 27533360 Free PMC article. No abstract available.
• Mechanisms of fluoroquinolone and macrolide resistance in Campylobacter spp.
  Payot S, Bolla JM, Corcoran D, Fanning S, Mégraud F, Zhang Q. Payot S, et al. Microbes Infect. 2006 Jun;8(7):1967-71. doi: 10.1016/j.micinf.2005.12.032. Epub 2006 Mar 29. Microbes Infect. 2006. PMID: 16713726 Review.
• Antimicrobial susceptibility of pneumococcal isolates causing bacteraemic pneumococcal pneumonia: analysis using current breakpoints and fluoroquinolone pharmacodynamics.
  Feldman C, Brink AJ, von Gottberg A, Wolter N, de Gouveia L, Perovic O, Klugman KP. Feldman C, et al. Int J Antimicrob Agents. 2010 Jul;36(1):95-7. doi: 10.1016/j.ijantimicag.2010.02.021. Epub 2010 Apr 7. Int J Antimicrob Agents. 2010. PMID: 20378315 No abstract available.

Cited by

• Pregnancy related adverse events and congenital disorders associated with fluoroquinolones: A real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS).
  Xiang DC, Xie WL, Cheng GY, Yue M, Du XY, Jiang J. Xiang DC, et al. Heliyon. 2024 Sep 7;10(18):e37547. doi: 10.1016/j.heliyon.2024.e37547. eCollection 2024 Sep 30. Heliyon. 2024. PMID: 39309803 Free PMC article.
• N1-Benzofused Modification of Fluoroquinolones Reduces Activity Against Gram-Negative Bacteria.
  Laws M, Hind C, Favaron A, Jamshidi S, Evans B, Clifford M, Sutton JM, Rahman KM. Laws M, et al. ACS Omega. 2020 May 18;5(21):11923-11934. doi: 10.1021/acsomega.9b03910. eCollection 2020 Jun 2. ACS Omega. 2020. PMID: 32548371 Free PMC article.
• The Value of Fortified Aminoglycoside/Cephalosporin Treatment as First-Line Treatment and in Fluoroquinolone-Resistant Bacterial Keratitis.
  Dikmetaş Ö, Deniz Y, Kocabeyoğlu S, Başol M, İrkeç M. Dikmetaş Ö, et al. Turk J Ophthalmol. 2020 Oct 30;50(5):258-263. doi: 10.4274/tjo.galenos.2020.37346. Turk J Ophthalmol. 2020. PMID: 33342191 Free PMC article.
• Do fluoroquinolones increase aortic aneurysm or dissection incidence and mortality? A systematic review and meta-analysis.
  Chen C, Patterson B, Simpson R, Li Y, Chen Z, Lv Q, Guo D, Li X, Fu W, Guo B. Chen C, et al. Front Cardiovasc Med. 2022 Aug 9;9:949538. doi: 10.3389/fcvm.2022.949538. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36017083 Free PMC article.
• Bleeding events among patients concomitantly treated with direct oral anticoagulants and macrolide or fluoroquinolone antibiotics.
  Yagi T, Mannheimer B, Reutfors J, Ursing J, Giunta DH, Kieler H, Linder M. Yagi T, et al. Br J Clin Pharmacol. 2023 Feb;89(2):887-897. doi: 10.1111/bcp.15531. Epub 2022 Oct 9. Br J Clin Pharmacol. 2023. PMID: 36098510 Free PMC article.

References

1. 1. Hooper DC. New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis 2000;30:243–54. - PubMed
2. 1. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. Silver Spring (MD): US Food and Drug Administration, Center for Drug Evaluation and Research; updated 2016. Available: www.fda.gov/Drugs/DrugSafety/ucm500143.htm (accessed 2016 May 27).
3. 1. Canadian Antimicrobial Resistance Surveillance System — report 2016. Ottawa: Public Health Agency of Canada; 2016.
4. 1. Karlowsky JA, Hoban DJ, DeCorby MR, et al. Fluoroquino-lone-resistant urinary isolates of Escherichia coli from out-patients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance Study. Antimicrob Agents Chemother 2006;50:2251–4. - PMC - PubMed
5. 1. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999; 28:352–64. - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Europe PubMed Central
  • HighWire
  • Ovid Technologies, Inc.
  • PubMed Central

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information